复旦大学药学院青年副研究员，博士，硕士生导师。2018年5月毕业于美国内布拉斯加大学医学中心，获药学博士（Pharm.D.）学位。2018年8月进入复旦大学药学院。主要从事临床药物治疗、药学服务与药事管理研究。近五年主持上海市卫健委青年项目1项、上海市科委青年项目1项，参与国家自然科学基金面上项目2项；发表学术论文28篇，其中SCI论文23篇；参编“十四五”本科规划教材及英文专著2部。现担任中国药学会药物流行病学青委会委员、中国老年保健医学研究会精准健康医学分会委员、上海市生物医药行业协会精准医疗专委会委员、复旦大学医学科普青年联盟理事。2022年复旦大学“钟扬式教学团队”核心成员，药学院“法莫西”学生讲师团指导教师，承担《临床药物治疗学》《药物流行病学》《临床药学技能与实践》《医院药学》《药物临床评价》等多门本科、研究生课程及英文慕课的授课。2020年起，于复旦附属闵行医院及社区、中小学校开展糖尿病药学门诊、科普讲座等多项社会服务活动。
1. 临床药物治疗
2. 药学服务
3. 药事管理
2014年8月 - 2018年5月，美国内布拉斯加大学医学中心，临床药学专业，药学博士（Pharm.D.）
2010年9月 - 2014年6月，复旦大学药学院，药学专业，学士
2018年8月 - 至今，复旦大学药学院，青年副研究员
中国药学会药物流行病学青委会委员
中国老年保健医学研究会精准健康医学分会委员
上海市生物医药行业协会精准医疗专委会委员
1. 上海市科学技术委员会，青年项目，22692190600，上海市面向老年慢性病患者居家药学服务的制度设计，2022-03至2023-2，5万元，结题，主持。
2. 上海市卫生健康委员会，青年项目，20194Y0234，DPP-4抑制剂对2型糖尿病患者健康相关生活质量的影响：基于中文简版DQoL量表的真实世界研究，2020-01至2022-12，5万元，结题，主持。
3. 上海市药品监督管理局，重大课题，本市药品监管人才队伍建设的“十四五”前期规划研究，2020-04至2020-10，6万元，结题，主要参与人。
4. 国家自然科学基金委员会，面上项目，82173892，nab-PTX与PD-1抗体联用抗肿瘤增效作用及其机制的
研究，2022-01至2025-12，55万元，在研，参与。
5. 国家自然科学基金委员会，面上项目，81973389，基于生理药动学/药效学模型动态预测TKIs与华法林的体内相互作用及其协同调控机制的研究，2020-01至2023-12，55万元，在研，参与。
2022年复旦大学“钟扬式教学团队”
2022年长三角高校临床药学教学能力邀请赛，一等奖（个人）
2021年复旦大学上海医学院第三届课程思政教案大赛，二等奖（个人）
2023年11月起，任《中国临床药学杂志》青年编委
2022年1月起，任复旦大学医学科普青年联盟理事
1. 参编“十四五”普通高等教育本科规划教材《药理学》，科学出版社，ISBN：9787030692986，2021年11月出版
2. 参编英文专著《Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences》， Springer，ISBN：9789811538971，2020年6月出版
1. Feng Z, Tong WK, Zhang X, Tang Z (通讯作者). Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Front Pharmacol. 2023; 14:1226778.
2. Feng Z, Tong WK, Zhang X, Tang Z (通讯作者). Prevalence of depression and association with all-cause and cardiovascular mortality among individuals with type 2 diabetes: a cohort study based on NHANES 2005–2018 data. BMC Psychiatry. 2023; 23(1):490.
3. Gu M, Li A, Mak W, Dong F, Xu N, Zhang J, Shi Y, Zheng N, Tang Z, He Q, Ruan C, Guo W, Xiang X, Wang C, Han B, Zhu X. Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. Front Pharmacol. 2023; 14:1089862.
4. Yuan Y, Li Z, Wang K, Zhang S, He Q, Liu L, Tang Z, Zhu X, Chen Y, Cai W, Peng C, Xiang X. Pharmacokinetics of novel furoxan/coumarin hybrids in rats using LC-MS/MS method and physiologically based pharmacokinetic model. Molecules. 2023; 28(2):837.
5. Lin J, Li M, Mak W, Shi Y, Zhu X, Tang Z, He Q, Xiang X. Applications of in silico models to predict drug-induced liver injury. Toxics. 2022; 10(12):788.
6. Jia Q, He Q, Yao L, Li M, Lin J, Tang Z, Zhu X, Xiang X. Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview. Molecules. 2022; 27(24):8670.
7. Feng Z, Ye Y, Ye H, Tang Z (通讯作者). Changes in pharmaceutical retail market and regional inequality of community pharmacists accessibility in mainland China: a retrospective cross-sectional study. BMJ Open. 2022; 12:e063739.
8. Feng Z, Li X, Tong WK, He Q, Zhu X, Xiang X, Tang Z (通讯作者). Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Front Pharmacol. 2022; 13:894685.
9. Feng Z, Tong WK, Tang Z (通讯作者). Longitudinal trends in the prevalence and treatment of depression among adults with cardiovascular disease: An analysis of national health and nutrition examination survey 2009–2020. Front Psychiatry. 2022; 13:943165.
10. Tang Z (第一作者), Fan X, Feng Z, Han B, Guo N. Case Report: Rhabdomyolysis secondary to vildagliptin overdose in a suicidal attempt: A case report and brief literature review. Front Pharmacol. 2022; 13:955162.
11. Tang Z (第一作者), Shen C, Tong WK, Xiang X, Feng Z, Han B. Frailty in community-dwelling adults aged 40 years and over with type 2 diabetes: association with self-management behaviors. Int J Environ Res Public Health. 2022; 19(15):9092.
12. Zhang J, Tang Z, Guo X, Wang Y, Zhou Y, Cai W. Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene. Front Oncol. 2022; 12:933646.
13. 郭楠, 韩冰, 喻轶群, 王晓娟, 刘宏锐, 冯振, 唐至佳(通讯作者). 基于智慧医疗构建糖尿病药学门诊的必要性及应用初探. 中国临床药学杂志. 2022; 31(07):495-499.
14. 冯振, 叶桦, 唐至佳 (通讯作者). 社会药房执业药师针对处方药和非处方药开展药学服务的同异性. 中国临床药学杂志. 2022; 31(04):298-301.
15. Yuan Y, He Q, Zhang S, Li M, Tang Z, Zhu X, Jiao Z, Cai W, Xiang X. Application of physiologically-based pharmacokinetic modeling in preclinical studies: a feasible strategy to practice the principles of 3Rs. Front Pharmacol. 2022; 13:895556.
16. He Q, Bu F, Wang Q, Li M, Lin J, Tang Z, Mak WY, Zhuang X, Zhu X, Lin H, Xiang X. Examination of the impact of CYP3A4/5 on drug–drug interaction between schizandrol A/schizandrol B and tacrolimus (FK-506): a physiologically based pharmacokinetic modeling approach. Int J Mol Sci. 2022; 23(9): 4485.
17. 冯振, 白玛拉姆, 叶桦, 洪兰, 唐至佳 (通讯作者). 我国社会药房执业药师药学服务能力研究. 药物流行病学杂志. 2021; 30(05):342-346.
18. He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin H, Xiang X. Investigation of the impact of CYP3A5 polymorphism on drug-drug interaction between tacrolimus and schisantherin A/schisandrin A based on physiologically-based pharmacokinetic modeling. Pharmaceuticals. 2021; 14(3):198.
19. Li M, He Q, Yao L, Wang X, Tang Z, Zhu X, Lin H, Xiang X. Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study. Pharmaceuticals. 2021; 14(11):1194.
20. Wang Z, Xiang X, Liu S, Tang Z, Sun H, Parvez M, Ghim J, Shin J, Cai W. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib. Drug Metab Pharmacokinet. 2021; 39:100362.
21. Tang Z (第一作者), Jiang X, Hong L, Feng Z, He Q, Yuan J, Xiang X. Validation of the simplified Chinese version of the brief Diabetes Quality of Life (DQoL) questionnaire based on a cross-sectional study. Int J Environ Res Public Health. 2020; 17(23):8792.
22. Tang Z (第一作者), Lhamu P, Ye H, Hong L, Xiang X. Current perceptions and improvement approaches of pharmaceutical care capacity of community pharmacists: a quantitative analysis based on survey data at Chinese chain pharmacies. Int J Environ Res Public Health. 2020; 17(20):7482.
23. 唐至佳 (第一及通讯作者), 叶桦. 关于部分发达国家（执业）药师继续教育管理现状分析. 中国药事. 2020; 34(12):1408-1413.
24. Wu W, Wang Y, Tang Z, Gao Y, Huo Y. Regulatory oversight of cell therapy in China: Government's efforts in patient access and therapeutic innovation. Pharmacol Res. 2020; 158:104889.
25. Wang Z, Xue Y, Sun H, Zhang Z, Tang Z, Liu S, Cai W. Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. J Food Sci. 2020; 85(4):1285-1291.
26. Wu W, Tang Z (共同一作), Chen J, Gao Y. Pediatric Drug Development in China Reforms and Challenges. Pharmacol Res. 2019; 148:104412.
27. 唐至佳 (第一及通讯作者), 叶桦. 执业药师资格考试电子化的可行性探讨. 中国药事. 2019; 33(1):26-31.
28. Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, Yang J, Xiang X. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. Biomed Pharmacother. 2019; 117:109095.
29. Wang L, Fan Z, Zhang J, Changyi Y, Huang C, Gu Y, Xu Z, Tang Z, Lu W, Wei X, Li C. Evaluating tumor metastatic potential by imaging intratumoral acidosis via pH-activatable near-infrared fluorescent probe. Int J Cancer. 2015; 136(4):E107-16.1.
